

ASX Release Stock Code: PRR

Monday, 13 October 2008

CANADIAN PATENT GRANTED FOR PRIMA OVARIAN CANCER VACCINE

Australian cancer treatment development company Prima BioMed Ltd ("Prima") (ASX: PRR) is pleased to announce that its subsidiary, Cancer Vac Pty Ltd, has been granted a patent covering its ovarian cancer immunotherapy product, MFP, by the Canadian Patent Office.

The patent titled, **Antigen carbohydrate compounds and their use in immunotherapy**, Patent Number 2135833 claims priority from November 1994 and expires in November 2014

The granted patent claims protect the manufacture of an immunotherapy comprising the patient's own dendritic cells that have been pulsed with a tumour antigen conjugated to mannan fusion protein (MFP). The granting of the Canadian patent strengthens Prima's development pipeline as the granted claims cover multiple antigens that may potentially be conjugated to MFP, not just those antigens associated with ovarian cancer.

The granting of the Canadian patent is exciting for the company as it represents the final major territory to be granted for the MFP product. Patents have already been granted in Australia, the USA (x 2), Europe and Japan.

Prima is currently developing an ovarian cancer vaccine, CVac[™] that has successfully completed Phase II trials as a maintenance therapy for women with end stage ovarian cancer. An investigational new drug (IND) application has been submitted with the US FDA for the ongoing development of CVac[™] in the US market.

For further information please contact:

Mr Martin Rogers
Director

Prima BioMed

Ph: 02 9232 4420, 0428 268 357

E: martin.rogeres@primabiomed.com.au

James Moses

Partner

Fortbridge Consulting

Ph: 0420 991 574

E: james.moses@fortbridge.com

About Prima Biomed Ltd

Prima Biomed (ASX: PRR) is a biotechnology company based in Sydney, Australia. The Company is focused on technologies in the fields of immunology and cancer immunotherapy. Prima is focused on developing a dendritic-cell based immunotherapy targeting mucin-1 tumour expressed antigen. Prima's lead product, CVac[™] has completed Phase IIa clinical development in Ovarian Cancer.

For further information, visit www.primabiomed.com.au

About CVac[™]

CVac[™] is an experimental therapy consisting of a patient's own dendritic cells primed with a tumour antigen (Mucin-1) and an adjuvant, Mannan Fusion Protein (MFP) currently being investigated in clinical trials.

MFP refers to the form in which the target protein of the CVac™ immunotherapy is presented to the immune system. The mannan used is a chain of mannose molecules that is oxidised and linked to the cancer protein (Mucin-1). Mannan stimulates the immune system and it is the mannan that results in rapid uptake of Mucin-1 into the dendritic cells of the immune system via the mannose receptor on the cell surface. Once the MFP is inside the dendritic cell, enzymes digest the Mucin-1 and fragments of Mucin-1 are presented on the dendritic cell surface. This presentation results in the stimulation of certain cells of the immune system to target Mucin-1 on the surface of the cancer cells.

About Ovarian Cancer

Ovarian cancer causes a significant burden of disease accounting for 5% of all cancer deaths and is the fifth leading cause of death in women in Canada, the U.S., and Europe. According to the American Cancer Society, in 2006 there are an estimated 20,000 new cases and more than 15,000 deaths from ovarian cancer in the U.S. alone. The front-line treatment for ovarian cancer is typically a combination of a taxane and a platinum drug. An initial response rate of approximately 70 percent to this type of chemotherapy regimen can be anticipated. In spite of initial response rates, recurrence rates among ovarian cancer patients are high and overall long-term survival has not changed significantly over the past 40 years, with five-year survival rates at less than 20 percent.

This release may contain forward-looking statements. Various factors could cause actual results to differ materially from those projected in forward-looking statements, including those predicting the timing and results of clinical trials, interpretation and implications of such results, availability or adequacy of financing, the sales and marketing of commercial products or the efficacy of products. Although the Company believes that the forward - looking statements contained herein are reasonable, it can give no assurance that the Company's expectations are correct. All forward - looking statements are expressly qualified in their entirety by this cautionary statement.

Prima BioMed Ltd, Suite 1705, 109 Pitt Street, Sydney, NSW Australia 2000
Ph: +61 (0)428 268 357 Fax: + 61 (0)2 9232 4450
www.primabiomed.com.au
ABN 90 009 237 889